Sign In
Buy AMGN
$338.22
+9.96 (+3.03%)
At Close: Jun 03, 2026
Amgen Shares Fall on Weight-Loss Drug Tummy Troubles
04:15pm, Monday, 23'rd Jun 2025
At the highest dosage of MariTide, 27% of patients stopped the drug due to a gastrointestinal adverse event.
Low start dose of Amgen experimental weight-loss drug limits side effects
02:40pm, Monday, 23'rd Jun 2025
People started on a low dose of Amgen's long-acting experimental obesity drug MariTide lost as much weight as those given high doses but with milder side effects, according to full results of a mid-st
MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and Delivered Significant Cardiometabolic Improvement
Amgen Expands Development Plans For Highly Anticipated Obesity Drug
02:30pm, Monday, 23'rd Jun 2025
Amgen said Monday it's expanding development plans for its weight-loss drug, MariTide, to include cardiovascular conditions and sleep apnea.
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
10:01am, Friday, 20'th Jun 2025
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
AMGEN'S PHASE 2 MARITIDE DATA TO BE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS
09:00am, Wednesday, 18'th Jun 2025
MariTide is the First Monthly or Less Frequently Dosed Peptide-Antibody Conjugate Being Investigated for the Treatment of Obesity and Type 2 Diabetes New Repatha® Data Provide Insight Into the Bene
Amgen: Imdelltra Data And Q1 Results Impress
10:30am, Saturday, 14'th Jun 2025
Despite the weak performance of Amgen's rare disease portfolio, it once again beat consensus non-GAAP EPS and revenue estimates. So, the main contributors to strengthening Amgen's balance sheet and im
Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider
06:51pm, Thursday, 12'th Jun 2025
Amgen (AMGN) closed at $297.29 in the latest trading session, marking a +1.88% move from the prior day.
Here's Why Amgen (AMGN) is a Strong Momentum Stock
10:56am, Wednesday, 11'th Jun 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Amgen Inc. (AMGN) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
05:28pm, Tuesday, 10'th Jun 2025
Amgen Inc. (NASDAQ:AMGN ) Goldman Sachs 46th Annual Global Healthcare Conference Call June 10, 2025 9:20 PM ET Company Participants James E. Bradner - Executive Vice President of Research & Developmen
Why Amgen (AMGN) is a Top Growth Stock for the Long-Term
10:50am, Tuesday, 10'th Jun 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Amgen (AMGN) is a Top Value Stock for the Long-Term
10:46am, Monday, 09'th Jun 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
10:06am, Monday, 09'th Jun 2025
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
2 Dividend Growth Stocks to Buy and Hold Forever
06:45am, Friday, 06'th Jun 2025
When broader equities are volatile, it's tempting to focus on what's going to happen in the near term. That's why some investors resort to panic selling -- they anticipate that things will get even wo
Amgen's Strategic Path - Navigating Patent Expiries With Promising New Therapies
02:31am, Friday, 06'th Jun 2025
Amgen faces major revenue risk from upcoming patent cliffs but has promising pipeline drugs like MariTide and olpasiran to offset losses. Recent financials show solid revenue growth and improved margi
